Associated Papers
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Pharmacogenetic determinants of warfarin in the Indian population.
Naushad SM et al.
Pharmacological Reports : Pr, 2021
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Arwood MJ et al.
Clinical Pharmacology and Therapeutics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2010
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G et al.
Blood Reviews, 2008
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T et al.
Thrombosis Research, 2007
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
DeLozier TC et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F et al.
Clinical Pharmacology and Therapeutics, 2004